Congress expands Medicaid preeclampsia screening—but leaves door open for diagnostic industry.

What it does

This bill directs the Secretary of Health and Human Services to issue guidance within 180 days on which preeclampsia screening and detection tests—including advanced biomarker tests—may be covered under Medicaid and the Children's Health Insurance Program (CHIP). It also requires the Secretary to provide technical assistance to states within 30 days of request to help them determine coverage for specific preeclampsia tests, though states are not required to request this assistance or adopt any particular coverage policy.

Why we flagged it

The bill's stated purpose is to improve maternal health outcomes by clarifying Medicaid/CHIP coverage of preeclampsia screening. However, its operative mechanism—directing HHS to 'consider' advanced biomarker tests and FDA-cleared devices—creates a regulatory pathway that will likely expand reimbursement for proprietary diagnostic products, making it a hybrid public-health and industry-benefit measure.

What the text implies

• The bill's requirement that HHS 'consider' biomarker tests and FDA-cleared devices may effectively create a presumption of coverage for new diagnostic products, shifting the burden to states to justify non-coverage rather than requiring manufacturers to justify coverage—a subtle but significant regulatory advantage for the diagnostic industry.
• By framing guidance around 'best practices' and 'early screening,' the bill may incentivize states to expand coverage beyond current practice, increasing Medicaid/CHIP spending on diagnostic testing without explicit appropriations or cost-benefit analysis.
• The 30-day technical assistance requirement creates a tight timeline that may favor well-resourced diagnostic companies and clinical laboratories capable of rapid engagement with state Medicaid agencies, potentially disadvantaging smaller or less-established test providers.
• The bill does not specify which biomarker tests are evidence-based or cost-effective, leaving HHS discretion to define 'consideration' criteria—a gap that could be filled by industry input or lobbying during the guidance-drafting process.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to preeclampsia screening for pregnant women on Medicaid and CHIP by clarifying which tests may be covered and providing states with evidence-based guidance. Preeclampsia is a leading cause of maternal mortality and morbidity, with disproportionate impact on Black women; earlier detection and management can prevent serious complications and deaths. The bill does not mandate coverage or impose costs on states—it provides guidance and technical assistance to help them make

Who stands to gain

• Diagnostic test manufacturers (biomarker test developers)
• Clinical laboratories (CLIA-certified high-complexity testing facilities)
• In vitro diagnostic (IVD) device companies
• Healthcare IT and laboratory information systems vendors

Named in the bill

HHS Secretary, Centers for Disease Control and Prevention (CDC), Medicaid, Children's Health Insurance Program (CHIP), FDA (Food and Drug Administration), CLIA (Clinical Laboratory Improvement Amendments), State Medicaid agencies, Managed care organizations

Where it stands

5 cosponsors: 3 Democrats, 2 Republicans.

• May 29, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 29, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $727,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Thomas Kean, the sponsor, reported $1,220,477 in PAC receipts in the 2026 cycle. $7,000 of that came from 1 PAC tied to these lobbying clients.

• Thermo Fisher Scientific Inc — $280,000 on 1 filing
• Laboratory Corporation of America Holdings — $270,000 on 1 filing
• American College of Obstetricians and Gynecologists — $96,000 on 1 filing
• March of Dimes — $60,000 on 1 filing
• Thermo Fisher Scientific Inc — $21,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.